Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.31 USD
Change Today -0.02 / -1.50%
Volume 688.8K
ATHX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

athersys inc (ATHX) Key Developments

Athersys, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Athersys, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, total revenues were $731,000 compared to $707,000 a year ago. Loss from operations was $6,893,000, compared to $7,389,000 a year ago. Net loss and comprehensive loss was $12,482,000 compared to $11,484,000 a year ago. The increase in net loss reflects a $496,000 reduction in loss from operations as offset by the impact of the $1.5 million increase in expense from the change in fair value of warrant liabilities. Basic and diluted net loss per common share was $0.16 against $0.15 a year ago. The net loss includes a non-cash expense of $5.6 million related to the change in fair value of warrant liabilities and $0.8 million related to stock-based compensation, working out to $0.08 a share. Excluding the items, the company would have reported a loss of $0.08. Cash provided by operating activities was $1.1 million compared to cash used by operating activities of $7.3 million in the first quarter of 2014.

Athersys, Inc. - Special Call

To present the recently announced interim results of its exploratory Phase 2 clinical study of the intravenous administration of MultiStem cell therapy to treat patients who have suffered an ischemic stroke

Athersys, Inc. to Report Q1, 2015 Results on May 11, 2015

Athersys, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 11, 2015

Athersys, Inc., Q1 2015 Earnings Call, May 11, 2015

Athersys, Inc., Q1 2015 Earnings Call, May 11, 2015

Athersys Inc. to Present Preliminary Results from Its Phase 2 Clinical Trial of its Investigational Biologic Product for the Treatment of Ischemic Stroke

Athersys Inc. is scheduled to present preliminary results from its phase 2 clinical trial of its investigational biologic product for the treatment of ischemic stroke on April 19, 2015. The experimental product in focus is MultiStem, a proprietary stem cell product that is manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. The phase II study of MultiStem for ischemic stroke was initiated in October 2011, and it completed enrollment last December. In this trial, stroke victims were administered MultiStem cells or placebo intravenously one to two days after the stroke had occurred. The primary endpoints for the study include safety over the first seven days following treatment and global stroke recovery at day 90, which assesses global disability (modified Rankin Score), neurological deficit (NIH stroke scale) and activities of daily living (Barthel Index). In addition to ischemic strokes, MultiStem is being explored in a range of indications like acute myocardial infarction, graft-versus-host disease and ulcerative colitis, to name a few. The company plans to launch phase 2 clinical studies of MultiStem in acute myocardial infarction and acute respiratory distress syndrome this year. The clinical trial results are capable of making or breaking the biotech stocks, and it remains to be seen how the MultiStem trial in ischemic stroke patients pans out.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATHX:US $1.31 USD -0.02

ATHX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.44 USD +0.02
Cytori Therapeutics Inc $0.66 USD -0.0708
NeoStem Inc $2.13 USD +0.07
Pluristem Therapeutics Inc $2.76 USD -0.04
StemCells Inc $0.68 USD -0.017
View Industry Companies
 

Industry Analysis

ATHX

Industry Average

Valuation ATHX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 63.9x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 45.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATHERSYS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.